RUBIVet: Rapid Urine based Bacteria Identification for Veterinary Applications

根据英国皇家兽医学院最近对532个兽医手术的调查，由于在2019冠状病毒病大流行期间采取了保持社会距离的措施，99%的兽医手术每周的交易量明显减少，66%的手术减少了51%或更多。532家兽医诊所中的451家也报告说，他们现在已经转向远程咨询，其中包括新的和重复的处方。近一个世纪以来，2天的实验室检测一直是诊断细菌感染的主要停留时间，对于远程咨询来说，这本质上是次优的。我们的动机是挑战这个市场明显缺乏创新，并解决现代兽医日益增长的挫败感，提供一种简单，一体化的动物尿液检测解决方案。在这个项目中，我们将与兽医市场的领导者Anvajo GmBH密切合作，在Anvajo现有的fluidlab R-300设备上提供快速细菌鉴定平台。这将在与金标准相比的时间、成本和不便方面保持与完整实验室分析相同的结果质量。

According to a recent survey of 532 veterinary surgeries by the Royal College of Veterinary Surgeons, 99% had noticeable reductions in weekly turnover, with 66% reporting reductions of 51% or more, as a result of social distancing measures implemented during the covid-19 pandemic. 451 of the 532 veterinary surgeries also reported that they had now moved to remote consultations which included new and repeat prescribing. 2-day laboratory testing has been the main stay for diagnosis of bacterial infections for nearly a century and is inherently sub-optimal for remote consultations. Our motivation is to challenge this distinct lack of innovation in this market and address the growing frustration amongst modern veterinarian with a simple, all-in-one solution to urine testing in animals.In this project, we will be working closely with veterinary market leaders Anvajo GmBH, to deliver a rapid bacterial identification platform on Anvajo's pre-existing fluidlab R-300 device. This would maintain the same quality of results expected from a full laboratory analysis at a fraction of time, cost and inconvenience of the gold standard.